2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1604

Impact of Time to Minimal Disease Activity and Quality of Life One Year after Diagnosis of Psoriatic Arthritis
Abstract Number: 1021

Impact of TLR7 Ligation in RA Pathology
Abstract Number: 2503

Impact of Tobacco Smoking on 1-Year Mortality Following Total Hip and Total Knee Arthroplasty Among Rheumatoid Arthritis Patients – a Danish Cohort Study Using Nationwide Health Care Registers
Abstract Number: 1128

Impact of Urate-Lowering Therapy on the Risk of Cardiovascular Events and All-Cause Mortality Among Individuals with Gout
Abstract Number: 2044

Impaired microRNA Processing in Neutrophils from Rheumatoid Arthritis Patients Confers Their Pathogenic Profile. Modulation By Biological Therapies
Abstract Number: 2900

Impaired TCR Signaling Paves the Way for Cytokine Hyper-Responsiveness in Arthritogenic T Cells
Abstract Number: 1949

Implementation of a Health Diary for Patients with Fibromyalgia
Abstract Number: 2309

Implementation of a Primary Prevention, Population-Based Virtual Osteoporosis Clinic Dramatically Increases the Number of Rural Veterans Receiving Osteoporosis Screening and Treatment
Abstract Number: 326

Implementation of a Treat-to-Target Quality Improvement Program for Rheumatoid Arthritis Management Using Real-Time Patient Reported Outcome Measures
Abstract Number: 1842

Implementation of an African American Popular Opinion Leader Model to Address Disparities in Lupus Knowledge and Care
Abstract Number: 338

Implementation of an Automated Phrase to Increase Awareness of Cardiovascular Risk in Rheumatoid Arthritis Patients in an Urban Fellows Rheumatology Clinic
Abstract Number: 328

Implementation of Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) Documentation in Systemic Lupus Erythematosus (SLE) Patients at an Academic Medical Center
Abstract Number: 295

Implementing a Staff Tobacco Cessation Protocol Increases Quit Line Referrals in a Community Rheumatology Practice
Abstract Number: 2304

Implication of Bone Turnover Marker Follow-up during Antiresorptive Therapy in Patients with Active Rheumatoid Arthritis on Immunosuppresssive Agents
Abstract Number: 1476

Implication of CXCL5 (Epithelial neutrophil-activating peptide 78) in the Development of Insulin Resistance in Patients with Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].